Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 502

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family

Open access
Flores, Elsa R., Sengupta, Shomit, Miller, John B., Newman, Jamie J., Bronson, Roderick, Crowley, Denise, Yang, Annie, McKeon, Frank, Jacks, Tyler·2005·Cancer Cell
DOI 10.1016/j.ccr.2005.02.019
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2005.02.019

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 38

  1. Ahomadegbe, 2000, Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers, Oncogene, 19, 5413, 10.1038/sj.onc.1203914 · DOI
  2. Chen, 2003, Differential expression of p53, p63 and p73 proteins in human buccal squamous-cell carcinomas, Clin. Otolaryngol., 28, 451, 10.1046/j.1365-2273.2003.00743.x · DOI
  3. Chen, 2004, Expression of p63 (TA and ΔN isoforms) in human primary well differentiated buccal carcinomas, Int. J. Oral Maxillofac. Surg., 33, 493, 10.1016/j.ijom.2003.10.023 · DOI
  4. Chen, 2004, p73 expression for human buccal epithelial dysplasia and squamous cell carcinoma: Does it correlate with nodal status of carcinoma and is there a relationship with malignant change of epithelial dysplasia?, Head Neck, 26, 945, 10.1002/hed.20098 · DOI
  5. Chen, 2004, Differential expression of p53, p63 and p73 protein and mRNA for DMBA-induced hamster buccal-pouch squamous-cell carcinomas, Int. J. Exp. Pathol., 85, 97, 10.1111/j.0959-9673.2004.0374.x · DOI
  6. Concin, 2004, Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo, Cancer Res., 64, 2449, 10.1158/0008-5472.CAN-03-1060 · DOI
  7. Di Como, 1999, p73 function is inhibited by tumor-derived p53 mutants in mammalian cells, Mol. Cell. Biol., 19, 1438, 10.1128/MCB.19.2.1438 · DOI · Paper page
  8. Flores, 2002, p63 and p73 are required for p53-dependent apoptosis in response to DNA damage, Nature, 416, 560, 10.1038/416560a · DOI · Paper page
  9. Gaiddon, 2001, A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain, Mol. Cell. Biol., 21, 1874, 10.1128/MCB.21.5.1874-1887.2001 · DOI · Paper page
  10. Hagiwara, 1999, Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers, Cancer Res., 59, 4165
  11. Hibi, 2000, AIS is an oncogene amplified in squamous cell carcinoma, Proc. Natl. Acad. Sci. USA, 97, 5462, 10.1073/pnas.97.10.5462 · DOI · Paper page
  12. Inokuchi, 2001, Establishment of a cell line with AML1–MTG8, TP53, and TP73 abnormalities from acute myelogenous leukemia, Genes Chromosomes Cancer, 32, 182, 10.1002/gcc.1181 · DOI
  13. Irwin, 2001, Role of the newer p53 family proteins in malignancy, Apoptosis, 6, 17, 10.1023/A:1009663809458 · DOI
  14. Irwin, 2003, Chemosensitivity linked to p73 function, Cancer Cell, 3, 403, 10.1016/S1535-6108(03)00078-3 · DOI · Paper page
  15. Jacks, 1994, Tumor spectrum analysis in p53-mutant mice, Curr. Biol., 4, 1, 10.1016/S0960-9822(00)00002-6 · DOI · Paper page
  16. Knudson, 1975, Genetics of human cancer, Genetics, 79, 305
  17. Knudson, 1986, Genetics of human cancer, Annu. Rev. Genet., 20, 231, 10.1146/annurev.ge.20.120186.001311 · DOI · Paper page
  18. Koga, 2003, Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder, Clin. Cancer Res., 9, 5501
  19. Lang, 2004, Gain of function of a p53 Hot spot mutation in a mouse model of Li-Fraumeni syndrome, Cell, 119, 861, 10.1016/j.cell.2004.11.006 · DOI · Paper page
  20. Mills, 1999, p63 is a p53 homologue required for limb and epidermal morphogenesis, Nature, 398, 708, 10.1038/19531 · DOI · Paper page
  21. Moll, 2003, The role of p63 and p73 in tumor formation and progression: Coming of age toward clinical usefulness, Clin. Cancer Res., 9, 5437
  22. Ng, 2000, Analysis of p73 in human borderline and invasive ovarian tumor, Oncogene, 19, 1885, 10.1038/sj.onc.1203512 · DOI
  23. Nozaki, 2001, p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade, Brain Pathol., 11, 296, 10.1111/j.1750-3639.2001.tb00400.x · DOI
  24. Park, 2000, Frequent alteration of p63 expression in human primary bladder carcinomas, Cancer Res., 60, 3370
  25. Park, 2004, Low expression of p63 and p73 in osteosarcoma, Tumori, 90, 239, 10.1177/030089160409000214 · doi:10.1177/030089160409000214
  26. Puig, 2003, p73 Expression in human normal and tumor tissues: Loss of p73α expression is associated with tumor progression in bladder cancer, Clin. Cancer Res., 9, 5642
  27. Senoo, 2004, p63 and p73 are not required for the development and p53-dependent apoptosis of T cells, Cancer Cell, 6, 85, 10.1016/j.ccr.2004.06.005 · DOI
  28. Strano, 2003, p73-mediated chemosensitivity: A preferential target of oncogenic mutant p53, Cell Cycle, 2, 348, 10.4161/cc.2.4.426 · DOI
  29. Strano, 2002, Physical interaction with human tumor-derived p53 mutants inhibits p63 activities, J. Biol. Chem., 277, 18817, 10.1074/jbc.M201405200 · DOI · Paper page
  30. Urist, 2002, Loss of p63 expression is associated with tumor progression in bladder cancer, Am. J. Pathol., 161, 1199, 10.1016/S0002-9440(10)64396-9 · DOI · Paper page
  31. Wang, 2002, p63 expression in normal, hyperplastic and malignant breast tissues, Breast Cancer, 9, 216, 10.1007/BF02967592 · DOI
  32. Yamaguchi, 2001, Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia, Leukemia, 15, 1729, 10.1038/sj.leu.2402265 · DOI
  33. Yamamoto, 2002, Expression of p73 gene, cell proliferation and apoptosis in breast cancer: Immunohistochemical and clinicopathological study, Oncol. Rep., 9, 729
  34. Yang, 1998, p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities, Mol. Cell, 2, 305, 10.1016/S1097-2765(00)80275-0 · DOI · Paper page
  35. Yang, 1999, p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development, Nature, 398, 714, 10.1038/19539 · DOI · Paper page
  36. Yang, 2000, p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours, Nature, 404, 99, 10.1038/35003607 · DOI · Paper page
  37. Yang, 2002, On the shoulders of giants: p63, p73 and the rise of p53, Trends Genet., 18, 90, 10.1016/S0168-9525(02)02595-7 · DOI · Paper page
  38. Zaika, 2002, DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors, J. Exp. Med., 196, 765, 10.1084/jem.20020179 · DOI · Paper page

Cited by

See all 502

Metadata

Authors
Flores, E. R., Sengupta, S., Miller, J. B., Newman, J. J., Bronson, R., Crowley, D., Yang, A., McKeon, F., & Jacks, T.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2005-04
Volume
7
Issue
4
Pages
363-373
ISSN
1535-6108 (ISSN-L)
DOI
10.1016/j.ccr.2005.02.019
OpenAlex
W2005013681
Cited by
502
References
1
FWCI
15.26
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. https://app.cochat.ai/papers/10.1016/j.ccr.2005.02.019
The paper
Flores, E. R., Sengupta, S., Miller, J. B., Newman, J. J., Bronson, R., Crowley, D., Yang, A., McKeon, F., & Jacks, T. (2005). Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. https://doi.org/10.1016/j.ccr.2005.02.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.